229 related articles for article (PubMed ID: 34628487)
21. Treatment adherence in tyrosinemia type 1 patients.
González-Lamuño D; Sánchez-Pintos P; Andrade F; Couce ML; Aldámiz-Echevarría L
Orphanet J Rare Dis; 2021 Jun; 16(1):256. PubMed ID: 34082789
[TBL] [Abstract][Full Text] [Related]
22. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
Morrow G; Tanguay RM
Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1.
Langlois C; Jorquera R; Finegold M; Shroads AL; Stacpoole PW; Tanguay RM
Biochem Pharmacol; 2006 May; 71(11):1648-61. PubMed ID: 16581029
[TBL] [Abstract][Full Text] [Related]
24. Live donor liver transplantation for type 1 tyrosinemia: An analysis of 15 patients.
Karaca CA; Yilmaz C; Farajov R; Iakobadze Z; Aydogdu S; Kilic M
Pediatr Transplant; 2019 Sep; 23(6):e13498. PubMed ID: 31155831
[TBL] [Abstract][Full Text] [Related]
25. The outcome of seven patients with hereditary tyrosinemia type 1.
Gokay S; Ustkoyuncu PS; Kardas F; Kendirci M
J Pediatr Endocrinol Metab; 2016 Oct; 29(10):1151-1157. PubMed ID: 27682708
[TBL] [Abstract][Full Text] [Related]
26. Oxidative stress among L-2-hydroxyglutaric aciduria disease patients: evaluation of dynamic thiol/disulfide homeostasis.
Cansever MS; Zubarioglu T; Oruc C; Kiykim E; Gezdirici A; Neselioglu S; Erel O; Yalcinkaya C; Aktuglu-Zeybek C
Metab Brain Dis; 2019 Feb; 34(1):283-288. PubMed ID: 30499066
[TBL] [Abstract][Full Text] [Related]
27. Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome.
Couce ML; Dalmau J; del Toro M; Pintos-Morell G; Aldámiz-Echevarría L;
Pediatr Int; 2011 Dec; 53(6):985-9. PubMed ID: 21752152
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.
Spiekerkoetter U; Couce ML; Das AM; de Laet C; Dionisi-Vici C; Lund AM; Schiff M; Spada M; Sparve E; Szamosi J; Vara R; Rudebeck M
Lancet Diabetes Endocrinol; 2021 Jul; 9(7):427-435. PubMed ID: 34023005
[TBL] [Abstract][Full Text] [Related]
29. The Liver in Tyrosinemia Type I: Clinical Management and Course in Quebec.
Halac U; Dubois J; Mitchell GA
Adv Exp Med Biol; 2017; 959():75-83. PubMed ID: 28755185
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review.
Geppert J; Stinton C; Freeman K; Fraser H; Clarke A; Johnson S; Sutcliffe P; Taylor-Phillips S
Orphanet J Rare Dis; 2017 Sep; 12(1):154. PubMed ID: 28893311
[TBL] [Abstract][Full Text] [Related]
31. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.
Al-Dhalimy M; Overturf K; Finegold M; Grompe M
Mol Genet Metab; 2002 Jan; 75(1):38-45. PubMed ID: 11825062
[TBL] [Abstract][Full Text] [Related]
32. Nitisinone treatment during two pregnancies and breastfeeding in a woman with tyrosinemia type 1 - a case report.
Zöggeler T; Ramoser G; Höller A; Jörg-Streller M; Janzen N; Ramoni A; Scholl-Bürgi S; Karall D
J Pediatr Endocrinol Metab; 2022 Feb; 35(2):259-265. PubMed ID: 34506697
[TBL] [Abstract][Full Text] [Related]
33. Dynamic thiol/disulfide homeostasis as oxidative stress marker in diabetic ketoacidosis.
Otal Y; Kahraman FA; Haydar FG; Erel Ö
Turk J Med Sci; 2021 Apr; 51(2):743-748. PubMed ID: 33356023
[TBL] [Abstract][Full Text] [Related]
34. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?
Koelink CJ; van Hasselt P; van der Ploeg A; van den Heuvel-Eibrink MM; Wijburg FA; Bijleveld CM; van Spronsen FJ
Mol Genet Metab; 2006 Dec; 89(4):310-5. PubMed ID: 17008115
[TBL] [Abstract][Full Text] [Related]
35. Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome.
Nobili V; Jenkner A; Francalanci P; Castellano A; Holme E; Callea F; Dionisi-Vici C
Pediatrics; 2010 Jul; 126(1):e235-8. PubMed ID: 20547648
[TBL] [Abstract][Full Text] [Related]
36. Oxidative Stress in Intoxıcation Type Inborn Errors of Metabolism using Thiol-Disulfide Ratio.
Cam V; Olgac A; Kilic M; Erel O; Neselioglu S; Kasapkara CS
J Coll Physicians Surg Pak; 2021 Jun; 31(6):663-667. PubMed ID: 34102777
[TBL] [Abstract][Full Text] [Related]
37. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone.
Bendadi F; de Koning TJ; Visser G; Prinsen HC; de Sain MG; Verhoeven-Duif N; Sinnema G; van Spronsen FJ; van Hasselt PM
J Pediatr; 2014 Feb; 164(2):398-401. PubMed ID: 24238861
[TBL] [Abstract][Full Text] [Related]
38. Thiol-disulfide homeostasis and ischemia-modified albumin as a marker of oxidative stress in patients with sarcopenia.
Özsürekci C; Şengül Ayçiçek G; Çalışkan H; Tuna Doğrul R; Neşelioğlu S; Özcan M; Doğu BB; Cankurtaran M; Erel Ö; Halil MG
Geriatr Gerontol Int; 2021 Jul; 21(7):584-589. PubMed ID: 34080286
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Nrg4 and thiol/disulfide homeostasis in patients with GDM.
Cindoglu C; Uyanikoglu H; Esercan A; Eren MA; Koyuncu I; Sabuncu T
Eur J Obstet Gynecol Reprod Biol; 2023 Jun; 285():105-109. PubMed ID: 37094427
[TBL] [Abstract][Full Text] [Related]
40. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
